
Introduction
Following a three-day hearing before the Court of Arbitration for Sport on 7-9 February 2024, the outcome of Simona Halep’s appeal against her doping suspension is imminent and eagerly awaited. In September 2023, the former world number 1 tennis star was banned for four years by an independent tribunal for breaches of Article 2 of the Tennis Anti-Doping Programme (“TADP”)[1], which broadly mirrors the WADA Code. The 2019 Wimbledon champion was held to have committed anti-doping rule violations (“ADRVs”) in respect of two distinct (but inter-connected) charges:
- the presence of Roxadustat[2] (prohibited anti-anaemia medication) in a urine sample collected during the 2022 US Open; and
- the use of a prohibited substance and/or method during 2022 on account of irregularities in her Athlete Biological Passport (“ABP”).
Aside from being one of the most high-profile sportspersons to be suspended for ‘intentional’ doping in recent memory, the first instance proceedings were notable for the number of experts deployed (four on each side, some of whom presented diametrically opposed opinions) and that the International Tennis Integrity Agency (“ITIA”) had sought a six-year sanction on the basis that there were “Aggravating Circumstances”[3]. Ms Halep has vehemently maintained her innocence (blaming a contaminated collagen supplement called Keto MCT) but, aged 31, her career and reputation hang in the balance.






